Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05446857 · ClinicalTrials.gov registry record · Phase 2
Glecaprevir/Pibrentasvir for the Treatment of PTSD
A Phase 2 study, sponsored by White River Junction Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT05446857 is a Phase 2 study that has completed, run by White River Junction Veterans Affairs Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT05446857, a Phase 2 study, has completed, sponsored by White River Junction Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
Interventions
- DRUG Glecaprevir / Pibrentasvir Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05446857
The ClinicalTrials.gov registry entry for NCT05446857 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is White River Junction Veterans Affairs Medical Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glecaprevir / Pibrentasvir Pill is the first listed.
NCT05446857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05446857 about?
NCT05446857 is a clinical study titled "Glecaprevir/Pibrentasvir for the Treatment of PTSD". An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
What is the current status of trial NCT05446857?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-04-01. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05446857?
The interventions under investigation include: Glecaprevir / Pibrentasvir Pill (DRUG).
Who is sponsoring clinical trial NCT05446857?
This trial is sponsored by White River Junction Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.